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 Introduction 
 Lithium carbonate is a medication widely used to treat 
bipolar affective disorders and acute manic depressive 
disorders. It has also been shown that lithium carbonate 
has antithyroid actions similar to those of inorganic io-
dide and has proven effective in doses of 300 mg 3–4 
times daily  [1] . It is used primarily to provide temporary 
control of thyrotoxicosis in patients who cannot take 
 thionamide drugs and/or iodide. When administered 
(800–1,200 mg daily) to patients suffering from Graves’ 
thyrotoxicosis, the serum T 4 and T 3 levels have been 
shown to decrease by as much as 35% and most patients 
become clinically euthyroid within 2 weeks of treatment. 
In a previous in vitro study, it was shown that lithium 
carbonate inhibited colloidal droplet formation of 3  and 
TSH-stimulated  131 I release from thyroid cells. Therefore, 
lithium carbonate is considered as a possible treatment 
for thyrotoxicosis as a ‘second-line’ drug  [2] . In patients 
with large goiters, but contraindications to thyroidecto-
my (i.e. cardiac disorders), lithium might represent a use-
ful adjunct to radioiodide to achieve, more rapidly, con-
trol of hyperthyroidism  [3] .
 In these reports, we present 5 patients with Graves’ 
disease and 1 patient with toxic multinodular goiter treat-
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 Abstract 
 Objective: The aim of this study was to elucidate the effec-
tiveness of lithium carbonate prior to thyroidectomy or ra-
dioiodide therapy in patients with thyrotoxicosis.  Subjects 
and Methods: Lithium carbonate was used as preoperative 
preparation or radioiodide therapy in 5 patients with Graves’ 
disease and in 1 patient with toxic multinodular goiter be-
cause of side effects of thionamide in 5 patients and ineffec-
tiveness of antithyroid medication in the remaining patient. 
 Results: All 6 patients had a benign course following treat-
ment without thyroid storm. No adverse effects or complica-
tions of lithium carbonate were observed.  Conclusion: This 
report shows that lithium carbonate can be safely used pre-
operatively or prior to radioiodide therapy in circumstances 
where antithyroid medications are contraindicated and are 
ineffective in obtaining an euthyroid status. 
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ed with lithium carbonate preoperatively or prior to ra-
dioiodide therapy. Lithium treatment was selected be-
cause of complications from thionamide medications in 
5 patients and inadequate control by thionamide in 1. 
 Case Reports 
 Case 1 
 A 35-year-old woman presented with symmetrical, tender and 
palpable purpuric lesions on her lower legs. She had been treated 
with propylthiouracil (PTU) for Graves’ disease for 6 years. Fur-
thermore, she suffered from Marfan’s syndrome with severe mi-
tral regurgitation, tricuspid regurgitation and rapid atrial fibril-
lation, which were aggravated by hyperdynamic circulatory con-
ditions associated with coexistent hyperthyroidism and Graves’ 
disease. Her mother also had Marfan’s syndrome.
 The patient had been treated with digoxin for heart failure for 
4 years. She developed an erythematous rash after receiving PTU 
for a few days. The patient was diagnosed as having PTU-induced 
antineutrophil cytoplasmic antibody (ANCA-MPO) positive vas-
culitis with markedly elevated ANCA anti-MPO antibodies. Her 
PTU therapy was discontinued, and she was treated with predni-
sone and cyclophosphamide. She was also given propranolol, cou-
madine and antibiotics. The patient became euthyroid after treat-
ment with lithium carbonate and radioactive iodide. Her skin le-
sions improved and her ANCA titers decreased to 41 U/ml after 6 
weeks of treatment.
 Case 2 
 A 63-year-old woman was diagnosed as having toxic multi-
nodular goiter. Due to elevated liver enzymes [ 6 3 times elevation 
of the upper limit of normal of liver function tests; AST: 112 IU/l 
(13–35), ALT: 168 IU/l (10–35)] lithium carbonate therapy was 
started rather than PTU or methimazole. Further laboratory ex-
amination showed positive antimitochondrial antibodies and liv-
er biopsy was consistent with primary biliary cirrhosis. Radioac-
tive iodine (RAI) therapy was the selected treatment. Prior to RAI 
she was placed on 300 mg of lithium 3 times a day for 2 weeks. She 
was euthyroid 2 weeks after starting lithium. After treatment 
with  131 I, she became euthyroid.
 Case 3 
 A 62-year-old woman diagnosed as having Graves’ disease and 
nodular goiter was scheduled for thyroidectomy. She was initially 
treated with PTU 4  ! 200 mg and propranolol 3  ! 40 mg but 
remained hyperthyroid. She therefore received  dexamethasone 
(1 mg/day) and lithium carbonate (300 mg t.i.d.). After 2 weeks of 
combination therapy she was euthyroid and was able to be oper-
ated on.
 Case 4  
 A 22-year-old woman was diagnosed as having Graves’ disease 
and hyperthyroidism while being evaluated for bilateral popliteal 
deep venous thrombosis. She was treated with coumadine (1  ! 
5 mg) and methimazole (3  ! 10 mg). As the therapeutic interna-
tional normalized ratio level had not been obtained and drug-
drug interaction was suspected, her methimazole was discontin-
ued  [3, 4] . Thereafter, lithium carbonate therapy was initiated. 
After 3 weeks, the euthyroid state was achieved and a therapeutic 
international normalized ratio level was also obtained. She was 
managed with RAI therapy.
 Case 5  
 A 40-year-old man had been receiving thyramazole 3 times 
daily (t.i.d.) for Graves’ disease. Because of elevated liver enzymes 
[ 6 3 times elevation of the upper limit of normal of liver function 
tests; AST: 102 IU/l (13–35), ALT: 112 (10–35)], the dose of thy-
ramazole could not be increased and he remained hyperthyroid. 
Later, thyramazole was discontinued and lithium carbonate 300 
mg t.i.d. was started; he became euthyroid with normal blood 
pressure and pulse rate in 3 weeks and was referred for thyroid-
ectomy.
 Case 6  
 A 37-year-old woman was treated with lithium carbonate 300 
mg t.i.d for Graves’ disease because she had elevated liver enzymes 
[ 6 3 times elevation of the upper limit of normal of liver function 
tests; AST: 59 IU/l (13–35), ALT: 188 IU/l (10–35)]. She was clini-
cally euthyroid with normal blood pressure and pulse rate in 2 
weeks and referred for thyroidectomy.
 Cases 5 and 6 were given lithium carbonate therapy prior to 
thyroidectomy because of concern for using antithyroid medica-
tions in patients with hepatic dysfunction. The thyroid function 
tests of the patients before and after lithium carbonate therapy are 
shown in  table 1 . All the patients had a successful outcome or 
postradiation ablation without postoperative thyroid storm or 
surgical recurrence.
 Discussion 
 Among the side effects of lithium carbonate, goiter de-
velopment and hypothyroidism are well known  [4] . The 
other effects on the thyroid include decreased iodide re-
Table 1. Thyroid function tests of patients before and after lithi-
um carbonate therapy
Cases Before lithium therapy After lithium therapy
FT3 
pg/ml
FT4 
ng/dl
TSH 
IU/ml
FT3 
pg/ml
FT4 
ng/dl
TSH 
IU/ml
Case 1 15.39 1.96 0.010 3.10 1.14 0.005
Case 2 6.88 1.87 0.005 3.72 1.25 0.005
Case 3 22.2 7.77 0.007 4.09 2.04 0.007
Case 4 2.44 0.6 0.005 2.01 0.431 0.819
Case 5 9.51 1.83 0.005 3.49 0.579 0.011
Case 6 5.73 2.79 0.007 2.24 2.87 0.011
FT3 = Free triiodothyronine; FT4 = free thyroxine; TSH = 
 thyroid-stimulating hormone.
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lease, impaired hormone synthesis and probably de-
creased T 4 deiodination.
 The indications for the use of lithium carbonate have 
not been properly established, probably because of the ef-
fectiveness of regular antithyroid drugs and the fear of 
possible complications of lithium carbonate treatment, 
including central nervous system disturbance (confu-
sion, blurring of vision, clumsiness, seizures and coma), 
arrhythmias (ventricular irritability, sinus node dysfunc-
tion and sinoatrial block), hyperparathyroidism and cal-
cium level changes, weight gain and nephrogenic diabe-
tes insipidus. However, serious complications rarely oc-
cur unless the lithium carbonate serum levels exceed 1.4 
mEq/l  [3] . One patient with severe thyrotoxicosis was 
treated with lithium carbonate prior to thyroidectomy. 
The intraoperative findings were unremarkable, with 
normal blood pressure and pulse  rate and minimal blood 
loss. The postoperative course was uneventful. This case 
demonstrates the effectiveness of lithium carbonate in 
thyrotoxic emergencies in which a rapid and safe inhibi-
tion of thyroid hormone secretion occurred  [5] .
 Radioiodide therapy is a well-established treatment for 
Graves’ hyperthyroidism. Several factors affect its effi-
cacy, including the short persistence of radioiodide in the 
thyroid gland. In hyperthyroid Graves’ patients, radioac-
tive iodide uptake is enhanced by TSH receptor antibody 
 [6] ; however, radioiodide is also rapidly discharged be-
cause of its increased turnover. The effectiveness of radio-
iodide therapy may be reduced by pretreatment with PTU 
but not with methimazole  [7] . Lithium carbonate can sig-
nificantly affect the kinetics of iodide by reducing its re-
lease from the thyroid gland, thus increasing its retention. 
However, lithium carbonate is rarely used to potentiate 
the therapeutic effect of radioiodide therapy. Beneficial 
effects of lithium carbonate in combination with radio-
iodide have been reported in cases of thyroid carcinoma 
 [8] and in a nonrandomized study of Graves’ disease  [9] . 
However, lithium carbonate is not recommended for gen-
eral use in Graves’ disease but only in the patients with 
very short effective half-life in whom the required thyroid 
dose may occasionally not be achieved because too much 
activity  would otherwise be needed  [10] .
 A short course of lithium carbonate therapy can be 
considered a useful adjunct to RAI therapy for obtaining 
a more rapid control of thyrotoxicosis and avoiding its 
transient exacerbation because of methimazole with-
drawal prior to RAI administration  [11] or in patients 
who cannot tolerate or do not respond to thionamides 
 [12] . In these reports  [11, 12] as in our 3 cases, the patients 
did not show any abnormality in thyroid function tests 
or any other complications. 
 In patients with large goiters but contraindications to 
thyroidectomy (i.e. cardiac disorders), as in case 1 of the 
present study, lithium carbonate treatment possibly rep-
resents a useful adjunct to radioiodide to achieve a more 
rapid control of hyperthyroidism. In this regard, an ad-
ditional important effect of the addition of lithium car-
bonate was the lack of serum free thyroxine and free tri-
iodothyronine surge which was observed shortly after 
radioiodide therapy. This effect might be related to radio-
iodide-induced destruction, as suggested by the concom-
itant rise in serum thyroglobulin concentrations, or to 
the prevention of thyroid hormone surge after antithy-
roid drug withdrawal. This effect might be particularly 
beneficial in older patients with an underlying cardiac 
disease. Although none of our patients suffered from any 
eye complications, we believe that the combined treat-
ment with radioiodide plus lithium carbonate might also 
be favorable for Graves’ ophthalmopathy because of the 
lower risk of recurrence of hyperthyroidism, which is 
known to adversely affect the course of  eye diseases.
 Conclusion 
 These cases show that lithium carbonate can be safely 
used preoperatively or prior to RAI therapy in circum-
stances in which antithyroid medications cannot be used 
due to side effects or when they are ineffective in obtain-
ing the euthyroid state.
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